{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:42:39Z","timestamp":1768459359943,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.breast.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T03:45:20Z","timestamp":1664336720000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2\u2013 advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial"],"prefix":"10.1016","volume":"66","author":[{"given":"Javier","family":"Salvador Bofill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Moreno Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar Augusto","family":"Rodriguez Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Galve Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Hernando Melia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Maria","family":"Ciruelos Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Jim\u00e9nez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"De la Cruz Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Mart\u00ednez Ja\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Villanueva Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"de Toro Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Anton Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel Manuela","family":"Alvarez Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Gavila Gregori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Quiroga Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Vicente Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"De la Haba-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Gonzalez-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Diaz Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agusti","family":"Barnadas Molins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Cantos Sanchez de Ibarg\u00fcen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ignacio","family":"Delgado Mingorance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Bellet Ezquerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"de Casa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuncion","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2022.09.006_bib1","series-title":"Las cifras del c\u00e1ncer en Espa\u00f1a","year":"2021"},{"issue":"7","key":"10.1016\/j.breast.2022.09.006_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12094-016-1607-9","article-title":"Cancer incidence in Spain, 2015","volume":"19","author":"Galceran","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.breast.2022.09.006_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12094-018-02010-w","article-title":"SEOM clinical guidelines in advanced and recurrent breast cancer (2018)","volume":"21","author":"L\u00f3pez-Mu\u00f1iz Ji","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.breast.2022.09.006_bib5","first-page":"1","article-title":"Managing breast cancer in younger women: challenges and solutions","volume":"8","author":"Ademuyiwa","year":"2016","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"6","key":"10.1016\/j.breast.2022.09.006_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/tbj.12644","article-title":"Considerations for the treatment of young patients with breast cancer","volume":"22","author":"Menen","year":"2016","journal-title":"Breast J"},{"issue":"4","key":"10.1016\/j.breast.2022.09.006_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.breast.2022.09.006_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1530\/ERC-10-0262","article-title":"Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer","volume":"18","author":"Thangavel","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.breast.2022.09.006_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/ijms14010108","article-title":"Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance","volume":"14","author":"Garc\u00eda-Becerra","year":"2012","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.breast.2022.09.006_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2022.09.006_bib11","series-title":"Breast cancer treatment guidelines","author":"NCCN","year":"2022"},{"key":"10.1016\/j.breast.2022.09.006_bib12","series-title":"KisqaliR summary of product characteristics","author":"Camberley","year":"2017"},{"issue":"7","key":"10.1016\/j.breast.2022.09.006_bib13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.breast.2022.09.006_bib14","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2022.09.006_bib15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.breast.2022.09.006_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2022.09.006_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2022.09.006_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10549-021-06334-0","article-title":"Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population","volume":"189","author":"De Laurentiis","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2022.09.006_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4137\/CMO.S31586","article-title":"Delaying chemotherapy in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"9","author":"Brufsky","year":"2015","journal-title":"Clin Med Insights Oncol"},{"issue":"3","key":"10.1016\/j.breast.2022.09.006_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.breast.2022.09.006_bib21","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.09.006_bib22","first-page":"v104","article-title":"Interim results from CompLEEment-1 (A phase 3b study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results","volume":"30","author":"Salvador EMC","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2022.09.006_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-017-4523-y","article-title":"Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","volume":"167","author":"Sonke","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2022.09.006_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.rpor.2012.05.005","article-title":"Breast cancer in the elderly-Should it be treated differently?","volume":"18","author":"Tesarova","year":"2012","journal-title":"Rep Practical Oncol Radiother"},{"key":"10.1016\/j.breast.2022.09.006_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918809610","article-title":"Use of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: young International Society of Geriatric Oncology review paper","volume":"10","author":"Battisti","year":"2018","journal-title":"Ther Adv Med Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:45:31Z","timestamp":1760777131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977622001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"alternative-id":["S0960977622001606"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.09.006","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2\u2013 advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}